KZR•benzinga•
Why Kezar Life Sciences Shares Are Getting Hammered
Summary
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga